A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.
Impact
The bill has notable implications for state legislation regarding healthcare pricing transparency and affordability. It requires the board to conduct reviews on select drugs identified as having high costs or significant increases in price, thereby potentially limiting how these drugs are priced and reimbursed in the state. Annual reports to the General Assembly will be mandated, providing insights on price trends and recommendations for legislative improvements to enhance drug affordability.
Summary
Senate File 2238 aims to address prescription drug affordability issues in Iowa by establishing a Prescription Drug Affordability Board. This board is tasked with protecting stakeholders, particularly patients facing high costs, and preventing affordability challenges within the healthcare system. The bill outlines the goals and responsibilities of the board, which include monitoring drug prices and conducting affordability reviews for identified prescription drugs that may pose significant financial burdens.
Contention
Debate surrounds the potential effectiveness of the board in truly influencing drug affordability, with concerns raised about the bureaucracy involved in its implementation. Critics argue that the bill might not sufficiently address the root causes of high prescription costs, while proponents believe it is a crucial step toward greater price control and transparency in the pharmaceutical market. The creation of a stakeholder council, which includes diverse members such as drug manufacturers and patient representatives, is intended to foster balanced input and oversight, although it also raises questions about potential conflicts of interest and representation.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.